ट्रायल रडार AI | ||
|---|---|---|
क्लिनिकल ट्रायल NCT07336381 (Replexa) के लिए परिधीय धमनी रोग, परिधीय न्यूरोपैथी वर्तमान में भर्ती जारी है। सभी विवरणों के लिए क्लिनिकल ट्रायल रडार कार्ड दृश्य और AI खोज उपकरण देखें, या यहाँ कुछ भी पूछें। | ||
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy 10
The proposed...
और दिखाएँAn Exploratory Clinical Study Using the Replexa+ Device in Veterans With Lower Extremity Peripheral Artery Disease Experiencing Peripheral Neuropathy
- Replexa
- 29224
peripheral neuropathy
lower extremity artery disease
lower extremity neuropathy
PAD
| प्रतिभागी समूह/शाखा | हस्तक्षेप/उपचार |
|---|---|
प्रयोगात्मकIntervention In-home shortwave diathermy treatment. | Replexa shortwave diathermy Treatment with home use of the Replexa+ shortwave diathermy device twice daily for 3 months. |
| परिणाम माप | माप विवरण | समय सीमा |
|---|---|---|
Compare baseline and post-treatment lower extremity arterial dopplers to determine change in lower extremity arterial perfusion. | Patients will be treated twice daily for three months with the Replexa+ device. Lower extremity arterial dopplers (LEADs) will be assessed at baseline and post-treatment to determine improvement in lower extremity perfusion. | 3 months |
| परिणाम माप | माप विवरण | समय सीमा |
|---|---|---|
Identify the presence and role of inflammatory biomarkers in PAD. | Patients will undergo peripheral blood collection at baseline and post-treatment time points to compare levels of high sensitivity C-reactive protein (hsCRP). | 3 months |
Diagnosis of peripheral artery disease (PAD).
Participants must exhibit PAD severity, defined by the following manifestation and corresponding Rutherford classifications:
Claudication of the index limb (Rutherford Category 2 or 3- documented as pain with walking) in conjunction with one or more of the following:
- ankle brachial index (ABI) greater than or equal to 0.6 mmHg, as measured no more than 6 months prior to screening
- resting toe brachial index (TBI) greater than or equal to 0.4, as measured no more than 6 months prior to screening
Note: In cases where ankle and toe systolic pressures are unavailable due to calcification and/or toe amputation, collection of angiographic data is acceptable to determine locations of blockages or reduced perfusion.
Diagnosis of peripheral neuropathy, as evidenced by review of medical records.
Competent to give consent.
Age 18 years or older.
- Impaired skin integrity in the location(s) to be treated.
- Current wounds or ulcerations.
- Diagnosis of active bleeding tendencies, hemorrhage, or thrombosis.
- 2+ pitting edema in either lower extremity.
- Active infection defined as elevated white blood cell count >11,500/µL or fever >101.5 degrees Fahrenheit or currently taking antibiotic medication(s) for an active infection.
- Existence of metal hardware in the area(s) to be treated: Any patient with implanted electronic or metal device such as a pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, IUD, surgical staples or implanted metallic leads.
- Pregnant individuals.
- Presence of renal disease (creatinine > 2.5 mg/dl and estimated glomerular filtration rate (eGFR) <30 mL/min) or patients on chronic hemodialysis.
- History of skeletal tuberculosis.
- Patients, in the investigator's opinion, whose index limb condition is rapidly deteriorating and may require major amputation within 30 days of screening.
- Conditions that impair cognitive function.
- Severe concomitant disease(s), or any additional condition(s) which the investigator feels constitute(s) criteria for exclusion of a particular subject.
Indiana